PharmX Technologies Limited (AU:PHX)
ASX:PHX
Want to see AU:PHX full AI Analyst Report?
Total Valuation
PharmX Technologies has a market cap or net worth of AU$72.54M. The enterprise value is AU$69.26M.
Market CapAU$72.54M
Enterprise ValueAU$69.26M
Share Statistics
PharmX Technologies has 659,457,460 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding659,457,460
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
PharmX Technologies’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is 27.25%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)-0.01
Return on Invested Capital (ROIC)27.25%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee67.16K
Profits Per Employee-2.42K
Employee Count109
Asset Turnover0.39
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PharmX Technologies is ―. PharmX Technologies’s PEG ratio is 2.61.
PE Ratio―
PS Ratio9.40
PB Ratio4.32
Price to Fair Value4.32
Price to FCF-8.43
Price to Operating Cash Flow-8.09
PEG Ratio2.61
Income Statement
In the last 12 months, PharmX Technologies had revenue of 7.32M and earned -264.00K in profits. Earnings per share was 0.00.
Revenue7.32M
Gross Profit5.96M
Operating Income-1.42M
Pretax Income79.00K
Net Income-264.00K
EBITDA1.39M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was 775.00K and capital expenditures -10.00K, giving a free cash flow of 765.00K billion.
Operating Cash Flow775.00K
Free Cash Flow765.00K
Free Cash Flow per Share<0.01
Dividends & Yields
PharmX Technologies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.69
52-Week Price Change37.50%
50-Day Moving Average0.11
200-Day Moving Average0.13
Relative Strength Index (RSI)49.32
Average Volume (3m)1.01M
Important Dates
PharmX Technologies upcoming earnings date is Sep 1, 2026, TBA (Confirmed).
Last Earnings DateFeb 24, 2026
Next Earnings DateSep 1, 2026
Ex-Dividend Date―
Financial Position
PharmX Technologies as a current ratio of 3.33, with Debt / Equity ratio of 5.61%
Current Ratio3.33
Quick Ratio3.33
Debt to Market Cap0.00
Net Debt to EBITDA-2.36
Interest Coverage Ratio-45.90
Taxes
In the past 12 months, PharmX Technologies has paid 343.00K in taxes.
Income Tax343.00K
Effective Tax Rate4.34
Enterprise Valuation
PharmX Technologies EV to EBITDA ratio is 47.23, with an EV/FCF ratio of -8.03.
EV to Sales8.95
EV to EBITDA47.23
EV to Free Cash Flow-8.03
EV to Operating Cash Flow-8.06
Balance Sheet
PharmX Technologies has AU$4.17M in cash and marketable securities with AU$894.00K in debt, giving a net cash position of AU$3.28M billion.
Cash & Marketable SecuritiesAU$4.17M
Total DebtAU$894.00K
Net CashAU$3.28M
Net Cash Per Share<AU$0.01
Tangible Book Value Per Share<AU$0.01
Margins
Gross margin is 81.43%, with operating margin of -19.44%, and net profit margin of -3.61%.
Gross Margin81.43%
Operating Margin-19.44%
Pretax Margin1.08%
Net Profit Margin-3.61%
EBITDA Margin18.96%
EBIT Margin1.50%
Analyst Forecast
The average price target for PharmX Technologies is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast6.93%
EPS Growth Forecast-1700.00%